Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012092528 - TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS

Publication Number WO/2012/092528
Publication Date 05.07.2012
International Application No. PCT/US2011/067993
International Filing Date 29.12.2011
IPC
A61K 31/74 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
74Synthetic polymeric materials
CPC
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61K 31/198
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA],
A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Applicants
  • STRATEGIC SCIENCE & TECHNOLOGIES, LLC [US]/[US] (AllExceptUS)
  • FOSSEL, Eric, T. [US]/[US] (UsOnly)
Inventors
  • FOSSEL, Eric, T.
Agents
  • WALLER, Patrick, R.h.
Priority Data
61/427,99929.12.2010US
61/428,21329.12.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS
(FR) TRAITEMENT DE LA DYSÉRECTION ET AUTRES INDICATIONS
Abstract
(EN)
The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40 °C (at least about 104 °F), as compared to compositions lacking one or more of these.
(FR)
L'invention concerne en général l'administration transdermique de divers composés. Selon certains aspects, l'administration transdermique peut être facilitée par l'utilisation d'un environnement biophysique hostile. Un ensemble de modes de réalisation divulguent une composition à administration locale, comprenant un inhibiteur de la photodiestérase de type 5 et/ou des sels de celui-ci, et éventuellement, un environnement biophysique hostile et/ou un donneur d'acide nitrique. Dans certains cas, la composition peut être stabilisée au moyen d'une combinaison de polymère de stabilisation (tel que la gomme de xanthane, le KELTROL® BT et/ou le KELTROL® RD), de propylène glycol, et d'un tensio-actif de polysorbate tel que le Polysorbate 20, ladite combinaison conférant, contre toute attente, une thermostabilité à la composition, par exemple à des températures élevées comme au moins 40°C (au moins environ 104°F), par rapport à une composition ne comprenant pas un ou plusieurs de ces éléments.
Latest bibliographic data on file with the International Bureau